Roche Palo Alto LLC

Syntex (u.s.a.) Inc.

F. Hoffmann-la Roche Ag

Russell Stephen Stabler

Ralph New Harris, Iii

David Bruce Repke

James M Kress

Robert J Greenhouse

Saul Jaime-Figueroa

Robert James Weikert

Hans Maag

Lawrence Emerson Fisher

Charles Alois Dvorak

Ann Marie Madera

Keena Lynn Green

Anthony Prince

Nancy Elisabeth Krauss

Francisco Javier Lopez-Tapia

Christine E Brotherton-Pleiss

Keith Adrian Murray Walker

Bradley E Loe

Pankaj D Rege

Robert Greenhouse

Ralph New Harris

Ralph New Harris Iii

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein m, p, q, Ar, Rand Rare as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

Tetralin and indane derivatives and uses thereof

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein X, Y, R, R, and Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

[1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators

Compounds of the formula I, II or III: or pharmaceutically acceptable salts thereof,wherein m, n, q, Ar, R, R, R, Rand Rare as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formulas I-III.

Compounds of the formula I: or pharmaceutically acceptable salts thereof,

Arylsulfonamidyl tetralin derivatives and uses thereof

The invention provides compounds of the formula: and pharmaceutically acceptable salts or prodrugs thereof, wherein m, p, q, r, A, E, X, Y, R, R, R, R, R, R, Rand are as defined herein. The invention also provides methods for preparing, compositions comprising, and methods for using compounds of formula I.

Quinolinone derivatives and uses thereof

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, Rand Rare as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formula I.

This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: wherein X, Y, and Z are O, S or NR, and the other substituents are as defined in the specification; and prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.

Heterocyclylakylamines as muscarinic receptor antagonists

Compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein m, Ar, R, R, and Rare as defined herein. The invention also provides methods for preparing, coompositions comprising, and methods for using compounds of Formula 1 for treatment of central nervous system disorders.

Aryloxy quinolines and uses thereof

Compounds of the Formula I: wherein m, n, k, A, X, Y, Z, Ar, R, R, R, and Rare as defined herein. The compounds are useful as 5-HT6 receptor antagonists. Also provided are compositions comprising, methods of using, and methods of making the subject compounds.

Growing community of inventors

Boulder Creek, CA, United States of America

Russell Stephen Stabler